Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel Charrow

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|January 23, 2013
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imigluceraseAri Zimran, Gregory M Pastores, Anna Tylki-Szymanska, et al.
Plos One|July 5, 2013
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERTSuhrad G Banugaria, Sean N Prater, Trusha T Patel, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry RegistryDominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Neuro-Oncology|April 5, 2012
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysisMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
The New England Journal of Medicine|July 4, 2019
C-Type Natriuretic Peptide Analogue Therapy in Children with AchondroplasiaRavi Savarirayan, Melita Irving, Carlos A Bacino, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|July 18, 2024
Expanding the phenotype of neurofibromatosis type 1 microdeletion syndromeJenny P Garzon, Andrea Patete, Lindsey Aschbacher-Smith, et al.
Annals of Neurology|April 18, 2014
Gender as a disease modifier in neurofibromatosis type 1 optic pathway gliomaMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
The Lancet. Child & Adolescent Health|November 20, 2023
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trialRavi Savarirayan, William R Wilcox, Paul Harmatz, et al.
Blood Cells, Molecules & Diseases|April 28, 2019
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.
Blood Cells, Molecules & Diseases|April 23, 2018
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|January 23, 2013
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imigluceraseAri Zimran, Gregory M Pastores, Anna Tylki-Szymanska, et al.
Plos One|July 5, 2013
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERTSuhrad G Banugaria, Sean N Prater, Trusha T Patel, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2013
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry RegistryDominique P Germain, Frank Weidemann, Ademola Abiose, et al.
Neuro-Oncology|April 5, 2012
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysisMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
The New England Journal of Medicine|July 4, 2019
C-Type Natriuretic Peptide Analogue Therapy in Children with AchondroplasiaRavi Savarirayan, Melita Irving, Carlos A Bacino, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|July 18, 2024
Expanding the phenotype of neurofibromatosis type 1 microdeletion syndromeJenny P Garzon, Andrea Patete, Lindsey Aschbacher-Smith, et al.
Annals of Neurology|April 18, 2014
Gender as a disease modifier in neurofibromatosis type 1 optic pathway gliomaMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
The Lancet. Child & Adolescent Health|November 20, 2023
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trialRavi Savarirayan, William R Wilcox, Paul Harmatz, et al.
Blood Cells, Molecules & Diseases|April 28, 2019
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.
Blood Cells, Molecules & Diseases|April 23, 2018
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.
Pageof 11